Arcturus develops an mRNA injection – El Financiero

Just over two years after the COVID-19 pandemic began, the company Arcturus Therapeutics of San Diego developed a new coronavirus vaccine.

This new messenger RNA (mRNA) vaccine seems to have shown that it could give the fight to injections from Moderna and Pfizer-BioNTech despite being more than a year behind them, and this It has significant advantages such as: easier storage, along with lower cost because its “self-amplifying” design allows for smaller doses.

Arcturus Therapeutics conducted a controlled clinical trialwhich had at least 17 thousand participants.

In a press release, the company announced that its SARS-CoV-2 vaccine showed 55 percent efficacy against symptomatic coronaviruswhile in severe cases and risk of death from the disease, its efficacy was 95 percent.

The other mRNA vaccines have an efficacy of symptomatic COVID of at least 90 percent, however, these were made with the original virus, while The new injection against the coronavirus was manufactured with the Delta and Ómicron strains.

The trial, which began in August 2021, gave participants two doses, each containing 5 micrograms of the self-amplifying mRNA, with an interval of 28 days. On the other hand, the Pfizer-BioNTech and Moderna vaccines use doses of 30 micrograms and 100 micrograms, respectively, for the first two injections.

This new vaccine may help make mRNA vaccines more accessible, and it is incorporates a process that makes it possible to store it at room temperature. Removing the cold chain from conventional mRNA injections makes it easier to transport.

At the moment the laboratories that worked on the vaccine already submitted efficacy data to regulators in Vietnamwhere the trial was conducted, for emergency use authorization and hopes to manufacture the product there.

–